Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

– Compass Therapeutics, Inc. (the “Organization”), a clinical-stage biopharmaceutical organization creating exclusive immunizer based therapeutics to treat malignant growth, today declared that it has valued a guaranteed public proposing to sell 35,715,000 portions of normal stock at a public contribution cost of $3.50 per share. Every one of the portions of normal stock are being presented by the Company

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
Also, the Company has conceded the financiers a 30-day choice to buy up to 5,357,250 extra portions of normal stock at the public contribution cost, less the endorsing rebate. Regarding the contribution, the Company additionally declared that its normal stock will start exchanging on the Nasdaq Capital Market under the image “CMPX” at the launch of exchanging on November 2, 2021, following its recently reported endorsement to list its normal stock on the Nasdaq Capital Market. The gross returns to the Company from the public contribution, prior to deducting guaranteeing limits and commissions and assessed offering costs, are relied upon to be around $125.0 million.

The contribution is relied upon to close on November 4, 2021, dependent upon standard shutting conditions. The Company means to utilize the net returns from the public contribution, along with its current money and money counterparts, for financing of continuous tasks including clinical preliminaries for the projects noted in the primer plan supplement, which might change dependent on clinical and preclinical outcomes.

I would like to receive information from suppliers sponsoring this content and willing to share the information above with business book 25.
SVB Leerink is going about as book-running director for the contribution. Raymond James and Associates, Inc., Wedbush Securities and H.C. Wainwright and Co. are going about as aloof book-running supervisors and The Benchmark Company and Roth Capital Partners are going about as co-directors for the contribution.

The protections depicted above are being presented by the Company as per a rack enlistment articulation on Form S-3 (No. 333-257821) that was proclaimed viable by the Securities and Exchange Commission on July 20, 2021. A primer outline supplement and going with plan identifying with the contribution were documented with the SEC and are accessible on the SEC’s site situated at www.sec.gov. A last plan supplement and going with outline portraying the particulars of the contribution will be documented with the SEC and will be accessible on the SEC’s site. Duplicates of the last outline supplement and the going with plan identifying with this contribution may likewise be acquired, when accessible, from SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by phone at (800) 808-7525, ext. 6105,

This public statement will not establish a proposal to sell or the sales of a proposal to purchase, nor will there be any offer of these protections in ward in which such a proposition, sales or deal would be unlawful before enrollment or capability under the protections laws of any such purview. Any deal, if by any stretch of the imagination, will be made exclusively through the outline supplement and going with plan framing a piece of the powerful enlistment articulation.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-centered biopharmaceutical organization creating exclusive neutralizer based therapeutics to treat numerous human illnesses. Compass’ logical spotlight is on the connection between angiogenesis, the insusceptible framework, and cancer development. The organization pipeline of novel item up-and-comers is intended to focus on various basic natural pathways needed for a viable enemy of growth reaction. These incorporate regulation of the microvasculature through angiogenesis-designated specialists, acceptance of an intense safe reaction by means of activators on effector cells in the cancer microenvironment, and lightening of immunosuppressive components utilized by growths to sidestep invulnerable observation. Compass intends to propel its item applicants through clinical advancement as both independent treatments and in mix with exclusive pipeline antibodies dependent on strong clinical and nonclinical information. The organization was established in 2014 and is settled in Boston, Massachusetts.

Forward-Looking Statements

This official statement contains forward-looking proclamations. Articulations in this public statement that are not simply recorded are forward-looking proclamations. Such forward-looking explanations incorporate, in addition to other things, proclamations in regards to the culmination of the contribution and the normal utilization of continues from the contribution, references to the Company’s item applicant, CTX-009, its turn of events, administrative plans with deference thereto and restorative potential thereof. Real outcomes could contrast from those projected in any forward-looking assertions because of various elements.

Such factors incorporate, among others, the Company’s capacity to raise the extra financing it should keep on pursueing its business and item advancement designs, the intrinsic vulnerabilities related with creating item applicants and working as an improvement stage organization, the Company’s capacity to distinguish extra item possibility for advancement, the Company’s capacity to create, complete clinical preliminaries for, get endorsements for and popularize any of its item up-and-comers, contest in the business in which the Company works and economic situations. These forward-looking assertions are made as of the date of this public statement, and the Company accepts no commitment to refresh the forward-looking assertions, or to refresh the motivations behind why real outcomes could contrast from those projected in the forward-looking assertions, besides as legally necessary. Financial backers ought to counsel all the data put forward in this and ought to likewise allude to the danger factor revelation set out in the reports and different archives the Company records with the SEC accessible at www.sec.gov.